Publications by authors named "F Le Marc'hadour"

The PMS2 gene is one of the DNA mismatch repair genes (MMR) implicated in Lynch syndrome (LS). A subset of PMS2 pathogenic variants (PVs) are splice variants mostly affecting canonical GT/AG splicing sequences. However, the majority of the intronic variants outside canonical splice sites remained as variants of unknown significance, even though some of them would alter the splicing process.

View Article and Find Full Text PDF
Article Synopsis
  • * The new formulation, trastuzumab emtansine (T-DM1), links trastuzumab to a cytotoxic drug to enhance delivery to cancer cells and reduce drug resistance.
  • * A case study revealed that a patient developed nodular regenerative hyperplasia after 12 months of T-DM1 treatment, leading to the cessation of the drug, though her cancer metastasis worsened; more research is needed on this side effect.
View Article and Find Full Text PDF

Objectives: The aim of this study is to compare to the guideline (1998 and 2001) the follow-up of Ascus cytological abnormalities among women aged 50-74 years who have participated at the combined breast, cervical and colorectal cancer screening programme from 1991 to 2000 in Isère, France.

Patients And Methods: The follow-up of 1154 women with Ascus smear was analysed. A woman was defined according follow-up if she have made a colposcopy or biopsy less than four months after one positive smear or if she has repeated three smears: 3-7 months and 10-14 months after the positive smear and 1 year after the last negative smear.

View Article and Find Full Text PDF

Objective: To assess the usefulness of core biopsy under ultrasonography (CBUS).

Materials And Methods: 165 US guided breast lesions biopsies were reviewed. Forty-eight underwent surgery and the 117 remaining cases were followed up for at least one year.

View Article and Find Full Text PDF

The expression of five cellular adhesion molecules (CAMs), CD54, CD58, CD11a, CD29 and CD49d, was studied in 113 B cell non-Hodgkin's lymphomas (NHL) and in normal B cells from 12 control lymph nodes. Rather than reporting the percentage of positive cells, which does not discriminate between NHL subtypes, we quantified the intensity of CAM expression using flow cytometry. Apart from CD49d the expression of all these CAMs was statistically different among the NHL subtypes as defined by the REAL classification.

View Article and Find Full Text PDF